Viewing nowCombinationHyperstar Tablet 40/5mg
Telmisartan 40mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
HanKook Hyutex Pharmaceutical Co., Ltd.

MFDS item code 201607200 · Approved 2016.12.21 · Insurance code 649103220
Treatment of essential hypertension not controlled with monotherapy
This medication helps patients with essential hypertension whose blood pressure is not properly controlled with either amlodipine or telmisartan monotherapy. The combination of the two components acts complementarily to dilate blood vessels and lower blood pressure. This helps reduce the burden on the heart and blood vessels and contributes to lowering the risk of complications. This medication is beneficial for managing blood pressure in cases where monotherapy is inadequate or ineffective. Regular use can lead to stable blood pressure control, which is advantageous for health.
The recommended dose of this medicine is 1 tablet once daily, taken with water, regardless of meals. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, a direct switch to this medicine may be considered as follows. - 40/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg. For patients taking telmisartan and amlodipine concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience (limited to this medicine 40/5 mg). ○ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended that treatment be initiated at a low dose and the dose increased gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine dosage regimen is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients Requiring Caution’). In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually.
The safety and efficacy of this medicine have not been established in pediatric patients 18 years of age or younger; therefore, administration of this medicine is not recommended.
This medication can cause severe side effects and risks of fetal death when used in pregnancy, especially during the second and third trimesters. Therefore, it must be discontinued immediately if pregnancy is confirmed. This medication should not be used in patients who are allergic to the active ingredients or similar components, pregnant or breastfeeding women, patients with severely impaired liver or heart function, and those with hypotension. Patients with mild liver function impairment or biliary obstruction, certain heart valve diseases, and severely impaired kidney function should use this medication with special caution. Common side effects include dizziness and peripheral edema, and there are rare reports of severe side effects, so if any unusual symptoms occur, medical consultation should be sought immediately. It is recommended not to use this medication during pregnancy and to consult with a doctor to choose another safe treatment if pregnancy is planned or ongoing. Patients with low fluid or sodium levels may experience excessively low blood pressure; prior to taking this medication, they should be fully replenished and should seek prompt assistance if symptoms of hypotension appear. Due to the risk of increased serum potassium levels, patients at risk of hyperkalemia should regularly check potassium levels through blood tests. Patients with impaired kidney function may experience changes in kidney function while taking this medication, so regular monitoring of kidney function is necessary. Patients with heart disease or congestive heart failure should be carefully observed as symptoms may worsen while taking this medication. This medication contains sorbitol, so patients with fructose intolerance should avoid it. Diabetic patients may have an increased risk of cardiovascular disease when taking this medication; hence, regular heart examinations are necessary, and coronary artery disease should be assessed even in the absence of symptoms. While taking this medication, drowsiness or dizziness may occur, so caution is advised when driving or operating dangerous machinery. This medication may interact with other antihypertensive drugs, so patients taking other medications should consult their doctor or pharmacist. In case of overdose, symptoms such as hypotension, arrhythmia, and dizziness may occur, which require immediate medical treatment, and this medication cannot be removed through hemodialysis. This medication should be stored out of the reach of children and protected from moisture and direct sunlight, ideally kept in its original packaging.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a light-resistant, closed container and kept at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication for a longer period.
White and light blue, double convex oval biconvex tablet
30 tablets/box [10 tablets/PTP*3], 30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
HanKook Hyutex Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
ILDONG Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.